<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00880971</url>
  </required_header>
  <id_info>
    <org_study_id>CH-L-015</org_study_id>
    <nct_id>NCT00880971</nct_id>
  </id_info>
  <brief_title>Postoperative Radiotherapy for Patients With IIIA (N2) Non-small Cell Lung Cancer</brief_title>
  <official_title>Post-Operative Radiation Therapy for Patients With pⅢA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: A Prospective Randomized Phase Ⅲ Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several important international randomized trials have shown that postoperative chemotherapy&#xD;
      contributed to the improvement on 5 year survival rate by about 4% for patients with&#xD;
      non-small cell lung cancer (NSCLC) after complete resection. But the overall survival rate&#xD;
      was relatively low and the local recurrence was still the dominant failure pattern for stage&#xD;
      IIIA (N2) disease even these patients received the postoperative chemotherapy. Several&#xD;
      meta-analyses have shown that postoperative radiotherapy (PORT) has no effect on the survival&#xD;
      improvement for patients with NSCLC after complete resection. However, sub-group analysis&#xD;
      based on the same dataset of these meta-analyses showed that the PORT with conventional&#xD;
      radiotherapy might be beneficial for stage IIIA (N2) disease. The 3D conform radiotherapy&#xD;
      (3D-CRT) and intensity modified radiotherapy (IMRT) can increase the radiation dose to the&#xD;
      target volume while decreasing the dose to risk organs comparing with the conventional&#xD;
      radiotherapy. So it is expected that PORT using 3D-CRT or IMRT after postoperative&#xD;
      chemotherapy will improve the local control and survival for stage IIIA (N2) NSCLC. Here, the&#xD;
      investigators designed a phase III randomized trial to compare the 3-year disease free&#xD;
      survival (DFS) and overall survival (OS) rates in patients with completely resected stage&#xD;
      IIIA (N2) NSCLC who receive adjuvant chemotherapy alone or adjuvant chemotherapy plus PORT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary: To determine whether administering adjuvant chemotherapy (four cycles of&#xD;
      platinum-based doublet regimen) plus PORT (50 Gy, 2 Gy once daily over 5 weeks) will improve&#xD;
      3-year DFS compared with adjuvant chemotherapy alone in patients with completely resected&#xD;
      stage IIIA (N2) NSCLC.&#xD;
&#xD;
      Secondary: To compare treatment-related toxic effects, 3-year OS, failure-free survival, and&#xD;
      the patterns of failure.&#xD;
&#xD;
      OUTLINE: Eligible patients were randomized equally, using simple randomization, to either&#xD;
      PORT or observation group.&#xD;
&#xD;
      Arm I: Patients undergo PORT using 3D-CRT or IMRT (50 Gy, 2 Gy once daily over 5 weeks) after&#xD;
      adjuvant chemotherapy.&#xD;
&#xD;
      Arm II: Patients undergo adjuvant chemotherapy.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year, every 6&#xD;
      months for 2 years, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 18, 2009</start_date>
  <completion_date type="Actual">February 29, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>3 years</time_frame>
    <description>Disease free survival measures in months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival measures in months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LRFS</measure>
    <time_frame>3 years</time_frame>
    <description>Loco-regional recurrence free survival measures in months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DMFS</measure>
    <time_frame>3 years</time_frame>
    <description>Distant metastasis free survival measures in months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure Patterns</measure>
    <time_frame>3 years</time_frame>
    <description>Loco-regional recurrence (LR) and Distant metastasis (DM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of thoracic radiotherapy</measure>
    <time_frame>6 months</time_frame>
    <description>CTC AE 3.0 is used to evaluate the toxicities, including radiation esophagitis (RE) and pneumonitis (RP).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">394</enrollment>
  <condition>Thoracic Neoplasms</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>PORT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo thoracic radiotherapy using 3D-CRT or IMRT (50 Gy, 2 Gy once daily over 5 weeks) after postoperative chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-PORT</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients undergo postoperative chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Postoperative 3D-CRT or IMRT</intervention_name>
    <description>Postoperative radiotherapy using 3D-CRT or IMRT techniques, 2 Gy per fraction, total 25 fractions (50Gy) over 5 weeks.</description>
    <arm_group_label>PORT</arm_group_label>
    <other_name>Postoperative radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Completely resected disease by lobectomy, bilobectomy. Complete dissection of lymph&#xD;
             nodes at levels 4, 7, and 10 in case of right-sided thoracotomy and at levels 4 (if&#xD;
             accessible), 5, 6, 7, and 10 in case of left-sided thoracotomy.&#xD;
&#xD;
          -  Histologically N2 disease after surgery. Negative margins&#xD;
&#xD;
          -  Has undergone chemotherapy of four cycles of platinum-based doublet regimen and no&#xD;
             recurrence and metastasis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  ECOG performance status &gt; 1&#xD;
&#xD;
          -  Post-operative FEV_1 &lt; 1 L (or &lt; 35% theoretical value, PO_2 &lt; 70 mm Hg, and PCO_2 &gt;&#xD;
             45 mm Hg)&#xD;
&#xD;
          -  Severe cardiac disease within the past 6 months, including the following: Arrhythmia,&#xD;
             Congestive heart failure, Infarction, Pacemaker&#xD;
&#xD;
          -  Severe pulmonary disease within the past 6 months&#xD;
&#xD;
          -  Other prior or concurrent neoplasm, except for basal cell carcinoma of the skin or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  Severe or uncontrolled systemic disease&#xD;
&#xD;
          -  Familial, social, geographic, or psychological conditions that would preclude study&#xD;
             participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luhua Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hosiptal, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Hosiptal, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995 Oct 7;311(7010):899-909.</citation>
    <PMID>7580546</PMID>
  </reference>
  <reference>
    <citation>Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet. 1998 Jul 25;352(9124):257-63.</citation>
    <PMID>9690404</PMID>
  </reference>
  <reference>
    <citation>Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med. 2000 Oct 26;343(17):1217-22.</citation>
    <PMID>11071672</PMID>
  </reference>
  <reference>
    <citation>Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol. 2006 Jul 1;24(19):2998-3006. Epub 2006 Jun 12.</citation>
    <PMID>16769986</PMID>
  </reference>
  <reference>
    <citation>Machtay M, Lee JH, Shrager JB, Kaiser LR, Glatstein E. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol. 2001 Oct 1;19(19):3912-7.</citation>
    <PMID>11579111</PMID>
  </reference>
  <reference>
    <citation>Matsuguma H, Nakahara R, Ishikawa Y, Suzuki H, Inoue K, Katano S, Yokoi K. Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: focusing on an effect of the number of mediastinal lymph node stations involved. Interact Cardiovasc Thorac Surg. 2008 Aug;7(4):573-7. doi: 10.1510/icvts.2007.174342. Epub 2008 Apr 15.</citation>
    <PMID>18413349</PMID>
  </reference>
  <reference>
    <citation>Douillard JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA; Adjuvant Navelbine International Trialist Association. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):695-701. doi: 10.1016/j.ijrobp.2008.01.044. Epub 2008 Apr 24.</citation>
    <PMID>18439766</PMID>
  </reference>
  <reference>
    <citation>Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 1;26(31):5043-51. doi: 10.1200/JCO.2008.16.4855. Epub 2008 Sep 22.</citation>
    <PMID>18809614</PMID>
  </reference>
  <reference>
    <citation>Ng R, Hasan B, Mittmann N, Florescu M, Shepherd FA, Ding K, Butts CA, Cormier Y, Darling G, Goss GD, Inculet R, Seymour L, Winton TL, Evans WK, Leighl NB; Working Group on Economic Analysis; Lung Disease Site Group; National Cancer Institute of Canada Clinical Trials Group. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 Jun 1;25(16):2256-61.</citation>
    <PMID>17538170</PMID>
  </reference>
  <reference>
    <citation>Dunant A, Pignon JP, Le Chevalier T. Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial. Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5017s-5021s.</citation>
    <PMID>16000606</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 13, 2009</study_first_submitted>
  <study_first_submitted_qc>April 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2009</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Luhua Wang</investigator_full_name>
    <investigator_title>Chairman of Thoracic Group, Clinical Professor, Radiation Oncology Department, Cancer Hospital&amp;Institute</investigator_title>
  </responsible_party>
  <keyword>Lung</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Thoracic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

